AJMC Post Conference Perspectives: ESC Congress 2024: Updates in Managing Heart Failure
Javed Butler, MD, MPH, MBA, discusses The American Journal of Managed Care® Post Conference Perspectives from European Society of Cardiology Congress 2024 in London, United Kingdom, focusing on key updates in heart failure management, including the implications of the FINEARTS-HF trial findings on finerenone, the role of β-blockers and dapagliflozin, and the need to address unmet needs in treatment strategies for patients with mildly reduced and preserved ejection fractions.
Episodes
September 24th 2024EP. 1: Overview of FINEARTS-HF Trial
Javed Butler, MD, MPH, MBA, discusses the FINEARTS-HF trial presented at European Society of Cardiology Congress 2024, highlighting its objective to evaluate finerenone in patients with heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, the randomized design, and results indicating a reduction in worsening HF events compared with placebo.
September 24th 2024EP. 2: Role of MRAs in HFmrEF and HFpEF
Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, emphasizing the role of nonsteroidal MRAs such as finerenone, and explore how the FINEARTS-HF results could translate into real-world benefits and inform the clinical pathway for these patients.
